hrp0092p3-185 | Multisystem Endocrine Disorders | ESPE2019

Final Height and Endocrine Complications in Patients with β-Thalassemia Intermedia: (TI) Our Experience in Non-Transfused Versus Infrequently Transfused Patients and Correlations with Liver Iron Content

TAWFIK SOLIMAN ASHRAF , Yassin Mohamed , Yassin Khadra , Abdulla Mohammad , De Sanctis Vincenzo

We evaluated the final height and the endocrine complications encountered in young adult patients with Thalassemia Intermedia (TI) followed at Hematology Section, Doha (Qatar) in relation to the liver iron content (LIC) in non-transfused versus infrequently transfused TI patients.Patients and Methods: This retrospective cohort study was performed on 28 young adults with TI who were randomly selected from the Hematology clinic, National C...

hrp0082p2-d3-438 | Growth Hormone (2) | ESPE2014

Does Priming with Sex Steroids Before GH Stimulation Test Increase the Diagnosis of Normal GH Secretion in Short Children?

Soliman Ashraf , De sanctis Vincenzo , Elgaali Elkhansa , Ahmed Hannah , Sabt Aml , Nassar Randa

Introduction: There is still controversy for priming with sex steroid before GH testing.Objective and hypotheses: We studied GH response to stimulation in 92 children >9 years with idiopathic short stature (HtSDS −2). They were divided randomly into two groups. Children in group 1 (n=50) were primed with premarin in girls and testosterone in boys and those in group 2 were not primed (n=42). All children were tested using stand...

hrp0082p3-d2-740 | Diabetes (3) | ESPE2014

Continuous Glucose Monitoring System in the Diagnosis of Early Glycemic Abnormalities in High-Risk Groups

Soliman Ashraf , Yassin Mohamed , Elawwa Ahmed , Elalaily Rania , De sanctis Vincenzo

Background: Continuous glucose monitoring (CGM) systems are an emerging technology that allows frequent glucose monitoring in real time.Objective and hypotheses: To assess the value of using CGM system (Medtronic) versus oral glucose tolerance (OGT) and HbA1c in the diagnosis of glycemic abnormalities (Prediabetes) in high-risk groups.Methods: We performed OGT and monitored glucose for 72 h using CGMS combined with four to five tim...

hrp0097p1-39 | Diabetes and Insulin | ESPE2023

Prevalence of Insulin-induced Lipohypertrophy (LD) in children and Adolescents with Type 1 Diabetes Mellitus in relation to important risk factors: Review of literature in the past 15 years in 11 countries

Soliman Ashraf , De Sanctis Vincenzo , Alaaraj Nada , Ahmed Shayma , Hamed Noor , Alyafei Fawzia

Abstract: Epidemiological and clinical data on LD in children and adolescents with T1DM are growing since 2010 because of the introduction of new insulin analogs and the use of insulin pumps (CSII). Many risk factors predispose to the occurrence of LD.Objectives and Methods: We performed an electronic search in PubMed, Google scholar and Web of Sciences to evaluate the global prevalence and possible risk factors of LD in...

hrp0097p1-242 | Diabetes and Insulin | ESPE2023

Prevalence of Insulin-induced Lipohypertrophy (LD) in Type 1 Diabetes Mellitus (T1DM): CSII versus MDIT and Children versus adults.: Review of literature in the past 15 years in 10 countries.

Soliman Ashraf , De Sanctis Vincenzo , Ahmed Shayma , Hamed Noor , Alyafei Fawzia , Alaaraj Nada

Lipohypertrophy (LD) represents the most common cutaneous complication of insulin therapy worldwide. Epidemiological and clinical data on LD in children and adolescents with T1DM are growing since 2010 because of the introduction of new insulin analogs and the use of insulin pumps (CSII).Objectives and Methods: We performed an electronic search in PubMed, Google scholar and Web of Sciences to evaluate the global prevalence and possible r...